This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.
Marzano A., Angelucci E., Astegiano M., Baratelli C., Biancone L., Bironzo P., et al. (2019). AISF position paper on HCV in immunocompromised patients. DIGESTIVE AND LIVER DISEASE, 51(1), 10-23 [10.1016/j.dld.2018.09.022].
AISF position paper on HCV in immunocompromised patients
Di Marco V.;Petta S.;Craxi A.;
2019-01-01
Abstract
This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PETTA DLD 2019.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
1.33 MB
Formato
Adobe PDF
|
1.33 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
